Join

Compare · GILD vs OKYO

GILD vs OKYO

Side-by-side comparison of Gilead Sciences Inc. (GILD) and OKYO Pharma Limited (OKYO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both GILD and OKYO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • GILD is the larger of the two at $161.88B, about 2971.3x OKYO ($54.5M).
  • Over the past year, GILD is up 22.6% and OKYO is up 3.5% - GILD leads by 19.1 points.
  • GILD has been more active in the news (8 items in the past 4 weeks vs 2 for OKYO).
  • GILD has more recent analyst coverage (25 ratings vs 2 for OKYO).
PerformanceGILD+22.62%OKYO+3.53%
2025-04-28+0.00%2026-04-24
MetricGILDOKYO
Company
Gilead Sciences Inc.
OKYO Pharma Limited
Price
$130.38-2.48%
$1.61+0.31%
Market cap
$161.88B
$54.5M
1M return
-5.67%
+1.57%
1Y return
+22.62%
+3.53%
Sector
Health Care
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
1992
2022
News (4w)
8
2
Recent ratings
25
2
GILD

Gilead Sciences Inc.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

OKYO

OKYO Pharma Limited

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Latest GILD

Latest OKYO